Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Connecticut, Maine, and New Hampshire

SAN DIEGO, March 23, 2016 /PRNewswire/ -- Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its wholly owned subsidiary, Sequenom Laboratories™, has entered into agreements with Anthem Blue Cross and Blue Shield Health Plans for the states of Connecticut, Maine, and New Hampshire, effective March 28, 2016. 

SEQUENOM logo.

The agreements provide in-network coverage for Sequenom Laboratories noninvasive prenatal tests (NIPT) for both high and average-risk pregnancies to Anthem's members in those states.

"Our commitment to women's health means doing all we can to ensure affordable access to our testing services. In keeping with this commitment, we continue to gain in-network status with the nation's leading health plans and are encouraged by increasing payor support of NIPT for average-risk pregnancies," said Dirk van den Boom, Ph.D., President and CEO of Sequenom.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women's health through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  For more information, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care.  Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.  Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the development of innovative products and services, actions to ensure affordable access to our testing services, continuing to gain in-network status with the nation's leading health plans and increasing payor support of NIPT for average-risk pregnancies.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO

 

SOURCE Sequenom, Inc.

For further information: Sequenom Contacts: Paul Goodson, Senior Director, Investor Relations and Corporate Communications, Sequenom, Inc., 858-202-9427, pgoodson@sequenom.com; Rachel Lipsitz, Media Contact, inVentiv Health PR Group, 858-449-9575, rachel.lipsitz@inventivhealth.com

print email rss pdf